Grifols Achieves EMA Certification for Egyptian Plasma Operations

An update from Grifols SA ( (GRFS) ) is now available.

On December 11, 2025, Grifols, S.A. announced that the European Medicines Agency (EMA) granted a Certificate of Compliance for plasma supplied by Grifols Egypt for Plasma Derivatives (GEPD), a joint venture with Egypt’s National Service Projects Organization. This certification, following a rigorous quality inspection, allows GEPD to manufacture and commercialize plasma products throughout Europe and other regions adhering to EMA legislation. This milestone positions Egypt as the first country in Africa and the Middle East with a fully integrated plasma collection and processing system meeting international standards, marking a significant achievement for Grifols in the global plasma industry.

The most recent analyst rating on (GRFS) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Grifols SA stock, see the GRFS Stock Forecast page.

Spark’s Take on GRFS Stock

According to Spark, TipRanks’ AI Analyst, GRFS is a Outperform.

Grifols SA’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. While technical indicators suggest potential bearish momentum, the company’s robust revenue growth and operational efficiency provide a solid foundation. Valuation is moderate, offering neither a significant discount nor premium.

To see Spark’s full report on GRFS stock, click here.

More about Grifols SA

Grifols, S.A. is a global healthcare company based in Spain, specializing in the production of plasma-derived medicines and other biopharmaceutical products. The company focuses on enhancing the health and well-being of people worldwide through innovative solutions in the plasma industry.

Average Trading Volume: 621,772

Technical Sentiment Signal: Hold

Current Market Cap: $7.72B

For detailed information about GRFS stock, go to TipRanks’ Stock Analysis page.